ArticleBulletin of the World Health Organization2016
A human rights-based approach to the reimbursement of expensive medicines.
Article in Bulletin of the World Health Organization, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The Ethics of Human Embryo Editing via CRISPR-Cas9 Technology: A Systematic Review of Ethical Arguments, Reasons, and Concerns.HEC forum : an interdisciplinary journal on hospitals' ethical and legal issues · 2025Pooled it
- A systematic review of moral reasons on orphan drug reimbursement.Orphanet journal of rare diseases · 2021Pooled it
- Challenges and Strategies for Improving Access to Cancer Drugs in Malaysia: Summary of Opinions Expressed at the 2nd MACR International Scientific Conference 2022.Cancer management and research · 2023Article
- Should COVID-19 Vaccines Authorized for Emergency Use Be Considered "Essential" Medicines?Health and human rights · 2021Article
- Universal access to essential medicines as part of the right to health: a cross-national comparison of national laws, medicines policies, and health system indicators.Global health action · 2020Article
- Legislating for universal access to medicines: a rights-based cross-national comparison of UHC laws in 16 countries.Health policy and planning · 2019Article
- Unlocking Access To Novel Medicines In China-A Review From A Health System Perspective.Risk management and healthcare policy · 2019Review
- Article
- How the Uruguayan Judiciary Shapes Access to High-Priced Medicines: A Critique through the Right to Health Lens.Health and human rights · 2018Article
- Essential medicines for universal health coverage.Lancet (London, England) · 2017Review
- [Judicial recourse and access to health technologies: opportunities and risksJudicialização e acesso a tecnologias em saúde: oportunidades e riscos].Revista panamericana de salud publica = Pan American journal of public health · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.